# Ablatotech Signals: Putative Target Q92743 in Wet Age-Related Macular Degeneration
Background
Wet age-related macular degeneration (AMD) is a severe form of AMD characterized by abnormal blood vessel growth under the retina, leading to rapid vision loss. Despite advancements in treatment, there is a continuous need for novel therapeutic targets to improve patient outcomes. In this context, the protein encoded by UniProt entry Q92743 has been identified as a putative target that warrants further investigation.
Data-mining rationale
The identification of Q92743 as a candidate target was achieved through a systematic cross-referencing of UniProt's reviewed human entries associated with wet AMD against seven microarray datasets available in the NCBI Gene Expression Omnibus (GEO). This approach aims to uncover potential targets that have not yet been explored in clinical settings, as evidenced by the absence of Q92743 in any registered Phase 1 or higher clinical programs.
Why prior analyses may have missed this
The GEO datasets analyzed in this study were generated before the widespread adoption of advanced statistical methods such as the empirical-Bayes approach implemented in the limma package. These older analyses may have lacked the statistical power to detect significant associations, potentially overlooking Q92743 as a relevant target. By re-analyzing these datasets with limma and applying the Benjamini-Hochberg false discovery rate (FDR) correction, previously hidden associations may be revealed.
Reasoning for further validation
To substantiate the candidacy of Q92743 as a therapeutic target for wet AMD, several experimental steps are recommended:
1. **Re-analysis of GEO datasets**: Utilize limma with an FDR threshold of < 0.05 to identify top differentially-expressed genes related to Q92743.
2. **Validation in independent cohorts**: Conduct quantitative PCR (qPCR) to verify the differential expression of Q92743 in an independent cohort of wet AMD patients.
3. **Tissue specificity assessment**: Explore the expression profile of Q92743 across various tissues using resources like GTEx and the Human Protein Atlas to determine its relevance to retinal pathology.
4. **Pathway context exploration**: Employ tools such as STRING and OmniPath to map the biological pathways involving Q92743, providing insights into its functional role in wet AMD.
5. **Druggability assessment**: If validated, evaluate the druggability of Q92743 using databases like DGIdb and ChEMBL to explore potential therapeutic interventions.
These steps are crucial for establishing Q92743 as a viable target for wet AMD treatment and for guiding future drug development efforts.